(firstQuint)Dialysis of Sugammadex in Participants With Severe Renal Impairment (Study 19.

4.

333) (P05773).

 The current trial was designed to evaluate the dialysability of the sugammadex-rocuronium complex in participants with severe renal impairment.

 A dose of 4.

0 mg/kg sugammadex was administered 15 minutes after administration of 0.

6 mg/kg rocuronium.

 Blood and dialysate samples were collected before, during and after hemodialysis/filtration, for calculation of clearance of sugammadex-rocuronium complex and assessment of rebound.

.

 Dialysis of Sugammadex in Participants With Severe Renal Impairment (Study 19.

4.

333) (P05773)@highlight

The clinical trial objectives were to evaluate the dialysability of the sugammadex-rocuronium complex; it's safety and efficacy in participants with severe renal impairment.

